

Northern (NHS) Treatment Advisory Group

Treatment Appraisal: Decision Summary

| | |
|------------------------------------|---|
| Date | April 5 th 2016 |
| Appraisal & Details | <p>e-Voke® (Nicovations Ltd) electronic inhaler to relieve and/or prevent withdrawal symptoms and reduce the cravings associated with tobacco dependence.</p> <p>The Northern (NHS) Treatment Advisory Group considered an appraisal of the first licensed e-cigarette e-Voke® for use as a smoking cessation aid.</p> |
| Recommendation | <p>The Northern (NHS) Treatment Advisory Group does not recommend the use of e-Voke® as a stop smoking aid on the NHS.</p> <p>The group was concerned about the lack of any data showing the benefits of using the e-Voke® device. Further data is required evaluating the use of e-Voke® as a stop smoking aid and comparing its use to other nicotine replacement therapies (NRT) that are currently used within the NHS.</p> <p>The NICE guidance on Tobacco Harm Reduction recommends that quitting all forms of nicotine use is the best option for smokers due to the long term risks associated with nicotine use therefore the use of e-Voke® was assessed as a stop smoking aid only.</p> |
| Clinical evidence summary | <p>There are no published trials using e-Voke®, however a clinical study was submitted to support the marketing authorisation application. This was a pharmacokinetic study with a crossover design, comparing bioavailability of nicotine, in 24 adult males, when delivered by e-voke® 10mg or 15mg cartridges, Nicorette® 15mg Inhalator or smoking a Benson and Hedges Gold cigarette. Nicotine exposure with e-voke® was higher than with the inhalator, but substantially lower than with smoking a cigarette. No other data is available for e-Voke® and this study did not include any evidence for effectiveness in smoking cessation.</p> |
| Safety | <p>The pharmacokinetic study concluded that e-Voke® was at least as safe as cigarette smoking in terms of nicotine exposure. No other safety events or outcomes were reported.</p> |
| Patient Perspective | <p>e-Voke® along with other e-cigarettes will to be available to purchase by patients should they favour the use of an e-cigarette, however those patients that want to quit and require nicotine replacement therapy will be offered more established NRT alongside support by the local stop smoking service which have been proven to be the most effective way to quit smoking altogether.</p> |
| Cost analysis summary | <p>A price for e-Voke® is not yet available. Estimates propose a cost of £20 per kit and £10 for refills – this equates to approximately £600 per patient per year.</p> |
| Financial impact PbR: In-tariff | <p>The financial impact of this recommendation is expected to be nil.</p> |